Flu-M [Inactivated split influenza vaccine]

BIOLOGICAL3 trials

Sponsors

St. Petersburg Research Institute of Vaccines and Sera

Conditions

Influenza

Phase 2

Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA

CompletedNCT05297994

St. Petersburg Research Institute of Vaccines and SeraInfluenza

Start: 2016-10-24End: 2017-03-09Updated: 2022-03-28

Phase 3

The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

CompletedNCT05089123

St. Petersburg Research Institute of Vaccines and SeraInfluenza

Start: 2020-03-03End: 2020-08-24Updated: 2022-01-06

The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

CompletedNCT05317767

St. Petersburg Research Institute of Vaccines and SeraInfluenza

Start: 2020-02-10End: 2020-09-14Updated: 2022-04-08